CORTISPORIN (hydrocortisone; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1975.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
CORTISPORIN is a fixed-combination otic solution containing hydrocortisone (corticosteroid), neomycin sulfate (aminoglycoside antibiotic), and polymyxin B sulfate (polypeptide antibiotic). It treats superficial bacterial infections of the external auditory canal by combining anti-inflammatory action with broad-spectrum bactericidal activity against gram-positive and gram-negative organisms. The formulation penetrates bacterial cell membranes, disrupts protein synthesis, and suppresses inflammatory response simultaneously.
This legacy otic antibiotic combination faces imminent loss of exclusivity with limited patent protection, suggesting reduced commercial support and smaller team footprint going forward.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on CORTISPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CORTISPORIN offers limited career mobility as a mature, approaching-LOE otic antibiotic with no linked job openings and minimal commercial investment. Career value derives from operational efficiency, compliance expertise, or transition management rather than growth or innovation.